コスモ・バイオ取扱いメーカーのHemaCare社の特長と共に、 leukopak 製品についてご紹介します。leukopak は、正常ドナーの末梢血から leukapheresis（白血球アフェレーシス）という方法により採取された製品で、単球、リンパ球、血小板、血漿、赤血球などの様々な血液細胞から構成されます。

1. HemaCare®
Leukopak Product
Comprehensive Products & Services
for BioResearch & Cellular Therapy
2017

2. HemaCare:HemaCare: Leading Provider of Apheresis Products,Leading Provider of Apheresis Products,
Blood Cells, & Apheresis Collection ServicesBlood Cells, & Apheresis Collection Services
• Market leader
– 250,000 apheresis procedures
– Over 39 years experience in blood collection and
banking
• Apheresis collections & human-derived blood
components
– Preclinical & clinical applications
• Biologics
• Immunotherapy
• Cell therapy
• Assay development
• Medical devices
• Support preclinical research, clinical studies from
Phase I to Phase III, & commercialization
– Recognized by Dendreon as a top apheresis
collection performer for PROVENGE® cell therapy
Headquarters
Los Angeles, California

3. HemaCare Quality Advantage:HemaCare Quality Advantage:
Our Donors Make the DIFFERENCEOur Donors Make the DIFFERENCE
Highly Characterized Donor Database
•We know our donors
 Recall donors / repeat collections
•They are qualified & tested for each donation
 Qualification, serological, & infectious testing performed
•We can recruit donors for specific investigator needs
 Age, gender, height, weight, ethnicity
 Medical history – vaccinations, diet, family history
 Lifestyle characteristics
 HLA type
 HIV, HepA, HepB, CMV testing
All donors are qualified per FDA regulations & IRB-approved informed consent.

4. Apheresis CollectionApheresis Collection
The HemaCare Advantage
•Established collection center
•Rapidly add new centers as needed
•Standardized protocols & procedures across all
sites
•24/7/365 support from clinical, logistics,
regulatory, & training experts
•Single point of contact
• Ability to optimize cell collection by controlling & qualifying the apheresis processes based on cGMP & cGTP principles
• Use of clinical-grade, serum-free, protein-free preservation media such as HypoThermosol® & CryoStor® enables worldwide
shipment of fresh or frozen cellular products, extending shelf-life of cells

5. Apheresis Collection-Apheresis Collection-
State of the art technologyState of the art technology
• Based upon unique centrifugal technology
• Allows for distinct separation of whole blood plasma-red blood cells-white blood cells
• Selected removal of targeted components into collection bag
• Return remaining blood components to the donor
Terumo Optia
COBE Spectra
Industry standard
>20 years

6. HemaCare High Quality Leukapheresis Raw MaterialHemaCare High Quality Leukapheresis Raw Material
Full Leukopak Count (x106
) ± SD
Total Nucleated
Cells
14,400 550
Mononuclear Cells 12,100 600
n= 1,202 leukapheresis products

7. Fresh or Frozen Leukopak- unique offeringFresh or Frozen Leukopak- unique offering
• HemaCare is the only provider of cryopreserved leukopak
– Use on demand
– Multiple portions for use at different times
– High recovery and viability
– Desirable for allogeneic cell therapy development, or cell
expansion protocols

8. Biopreservation MediaBiopreservation Media
Success in the regenerative medicine, biobanking, and drug discovery
industries depends on the shelf life and viability of cells, tissues, and organs
designated for research or clinical applications.
CryoStor®
Pre-formulated with 2, 5, 10%,
or a custom volume of USP-
grade DMSO, CryoStor yields
superior post-thaw cell viability,
recovery, and function. Serum-
free and protein-free!
HypoThermosol®
Protein-free, serum-free
hypothermic storage media are
designed for maximum shelf life
and shipping stability at 2-8°C.

9. Thank You!
Visit us at www.hemacare.com

10. Thank You!
Visit us at www.hemacare.com